Work

Genomic variability in the neuraminidase gene and antiviral susceptibility of influenza A(H1N1)pdm09 viruses isolated from hospitalized patients in Shiraz, Iran (2023–2024)

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background The 2009 influenza A(H1N1)pdm09 pandemic caused substantial global morbidity and mortality. Mutations in the neuraminidase (NA) gene may influence viral evolution, immune evasion, and susceptibility to neuraminidase inhibitors, highlighting the importance of continuous molecular surveillance. Methods Between November 2023 and December 2024, 300 respiratory samples were collected from patients with acute respiratory infections in Shiraz, Iran, and screened for influenza A(H1N1)pdm09 by real-time RT-PCR. Fourteen positive samples underwent full-length NA gene sequencing, amino acid substitution analysis, phylogenetic analysis, structural modeling, and molecular docking with oseltamivir and zanamivir. Phylogenetic comparison was performed using the historical pandemic reference strain A/California/07/2009 (NC_026434.1) to identify neuraminidase sequence divergence relative to the founding A(H1N1)pdm09 lineage. Results Sequence analysis identified 18 distinct amino acid substitutions in the NA gene among the 14 isolates. The most frequent substitutions were V241I and N369K (13/14, 92.9%), followed by N200S (4/14, 28.6%) and V394I (2/14, 14.3%). V241I and N369K are consistent with previously reported lineage-associated permissive substitutions in circulating A(H1N1)pdm09 viruses, whereas N386K has been associated with alteration of an N-linked glycosylation site. Screening of the NA sequences for established WHO-recognized neuraminidase inhibitor resistance-associated substitutions identified no major known resistance markers, including H275Y and I223V. Molecular docking suggested preserved predicted binding of oseltamivir and zanamivir to neuraminidase. Conclusion Influenza A(H1N1)pdm09 viruses isolated from hospitalized patients in Shiraz during 2023–2024 exhibited genetic variability in the neuraminidase gene while lacking established neuraminidase inhibitor resistance-associated substitutions. These findings provide sequence-based evidence consistent with the absence of established resistance markers among the analyzed isolates and emphasize the importance of continued molecular surveillance to monitor the emergence of clinically relevant NA mutations. Clinical Trial Registration Not applicable, as this study is observational and does not involve a clinical trial.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W4410096967
FWCI:
Cites: 23
Cited by:
Related to: 10